JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3433 Gefitinib hydrochloride

Target: EGFR

Summary: Potent EGFR inhibitor

insoluble in EtOH; ≥4.28 mg/mL
A3573 LY2801653

Target: MET

Summary: MET inhibitor

≥27.65 mg/mL
A3632 Motesanib

Target: VEGFR

Summary: Inhibitor of Flk-1/Flt-4/PDGFR-/c-Kit

≥42 mg/mL
A8219 Gefitinib (ZD1839)
3 Citation

Target: EGFR

Summary: Selective EGFR inhibitor

≥22.34 mg/mL
A2678 SU11274
2 Citation

Target: MET

Summary: C-Met inhibitor,potent and selective

≥28.4 mg/mL
A8320 PF-00562271

Target: FAK|Pyk2

Summary: FAK/Pyk2 inhibitor,potent and ATP-competitive

insoluble in EtOH; insoluble in H2O; ≥11.1 mg/mL
A8325 Tivantinib (ARQ 197)
2 Citation

Target: MET

Summary: C-Met inhibitor,non-ATP-competitive

≥18.47 mg/mL
A8345 PF-562271 HCl

Target: FAK|Pyk2

Summary: FAK/Pyk2 inhibitor

≥26.35 mg/mL
A8476 MK-2461

Target: FLT3|PDGFR|MET|Ron

Summary: C-Met (WT/mutants) inhibitor

≥24.8 mg/mL